Literature DB >> 23351840

Differentiation of pure vasogenic edema and tumor-infiltrated edema in patients with peritumoral edema by analyzing the relationship of axial and radial diffusivities on 3.0T MRI.

Zhi-gang Min1, Chen Niu, Netra Rana, Huan-mei Ji, Ming Zhang.   

Abstract

OBJECT: The purpose of this study was to analyze the relationship of axial diffusivity (AD) and radial diffusivity (RD) in peritumoral edema of high grade glioma, metastasis, and meningioma, and to differentiate tumor-infiltrated edema from pure vasogenic edema.
MATERIALS AND METHODS: Twenty patients with high-grade glioma and 16 with meningioma or metastatic tumor were enrolled in our study. All cases were confirmed by histopathological study. Diffusion tensor imaging (DTI) was performed in all patients. Peritumoral edema of high-grade glioma was considered tumor-infiltrated edema, and edema of meningioma or metastasis was considered pure vasogenic edema. Fractional anisotropy (FA), mean diffusivity (MD), AD, RD, regression coefficient of RD to AD (RCRD-AD), and tumor infiltration index (TII) in tumor-infiltrated edema and pure vasogenic edema were analyzed and compared. Receiver operating characteristic (ROC) curve analysis was conducted to demonstrate their differential effectiveness.
RESULTS: RCRD-AD in tumor-infiltrated edema (0.724±0.125) was significantly higher than that in pure vasogenic edema (0.571±0.111) (P=0.001). FA of tumor-infiltrated edema (0.175±0.025) was significantly lower than that of pure vasogenic edema (0.203±0.035) (P=0.007). Other parameters showed no significant difference between the 2 types of edema. ROC curve analysis showed RCRD-AD was the most effective parameter in distinguishing tumor-infiltrated edema from pure vasogenic edema. Using a threshold of 0.6, a sensitivity of 0.85 and specificity of 0.69 can be achieved with RCRD-AD.
CONCLUSION: Analysis of the AD and RD relationship may reflect differences in diffusion characteristics of edema surrounding high-grade glioma and meningioma or metastasis, and may be helpful in detecting peritumoral infiltration in high-grade glioma.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diffusion tensor imaging; Diffusivity; High-grade glioma; Meningioma; Tumor-infiltrated edema; Vasogenic edema

Mesh:

Year:  2013        PMID: 23351840     DOI: 10.1016/j.clineuro.2012.12.031

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  18 in total

1.  Evaluation of low-grade glioma structural changes after chemotherapy using DTI-based histogram analysis and functional diffusion maps.

Authors:  Antonella Castellano; Marina Donativi; Roberta Rudà; Giorgio De Nunzio; Marco Riva; Antonella Iadanza; Luca Bertero; Matteo Rucco; Lorenzo Bello; Riccardo Soffietti; Andrea Falini
Journal:  Eur Radiol       Date:  2015-08-30       Impact factor: 5.315

2.  Characterizing the peritumoral brain zone in glioblastoma: a multidisciplinary analysis.

Authors:  Jean-Michel Lemée; Anne Clavreul; Marc Aubry; Emmanuelle Com; Marie de Tayrac; Pierre-Antoine Eliat; Cécile Henry; Audrey Rousseau; Jean Mosser; Philippe Menei
Journal:  J Neurooncol       Date:  2015-01-06       Impact factor: 4.130

3.  Mesoscopic imaging of glioblastomas: Are diffusion, perfusion and spectroscopic measures influenced by the radiogenetic phenotype?

Authors:  Theo Demerath; Carl Philipp Simon-Gabriel; Elias Kellner; Ralf Schwarzwald; Thomas Lange; Dieter Henrik Heiland; Peter Reinacher; Ori Staszewski; Hansjörg Mast; Valerij G Kiselev; Karl Egger; Horst Urbach; Astrid Weyerbrock; Irina Mader
Journal:  Neuroradiol J       Date:  2016-11-19

4.  MR Fingerprinting of Adult Brain Tumors: Initial Experience.

Authors:  C Badve; A Yu; S Dastmalchian; M Rogers; D Ma; Y Jiang; S Margevicius; S Pahwa; Z Lu; M Schluchter; J Sunshine; M Griswold; A Sloan; V Gulani
Journal:  AJNR Am J Neuroradiol       Date:  2016-12-29       Impact factor: 3.825

Review 5.  Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone.

Authors:  Jean-Michel Lemée; Anne Clavreul; Philippe Menei
Journal:  Neuro Oncol       Date:  2015-07-22       Impact factor: 12.300

Review 6.  Tractography methods and findings in brain tumors and traumatic brain injury.

Authors:  Fang-Cheng Yeh; Andrei Irimia; Dhiego Chaves de Almeida Bastos; Alexandra J Golby
Journal:  Neuroimage       Date:  2021-10-18       Impact factor: 6.556

7.  Differentiation of edema and glioma infiltration: proposal of a DTI-based probability map.

Authors:  Friso W A Hoefnagels; Philip De Witt Hamer; Ernesto Sanz-Arigita; Sander Idema; Joost P A Kuijer; Petra J W Pouwels; Frederik Barkhof; W Peter Vandertop
Journal:  J Neurooncol       Date:  2014-07-31       Impact factor: 4.130

8.  Improved nTMS- and DTI-derived CST tractography through anatomical ROI seeding on anterior pontine level compared to internal capsule.

Authors:  Carolin Weiss; Irada Tursunova; Volker Neuschmelting; Hannah Lockau; Charlotte Nettekoven; Ana-Maria Oros-Peusquens; Gabriele Stoffels; Anne K Rehme; Andrea Maria Faymonville; N Jon Shah; Karl Josef Langen; Roland Goldbrunner; Christian Grefkes
Journal:  Neuroimage Clin       Date:  2015-01-20       Impact factor: 4.881

9.  Functional MRI vs. navigated TMS to optimize M1 seed volume delineation for DTI tractography. A prospective study in patients with brain tumours adjacent to the corticospinal tract.

Authors:  Carolin Weiss Lucas; Irada Tursunova; Volker Neuschmelting; Charlotte Nettekoven; Ana-Maria Oros-Peusquens; Gabriele Stoffels; Andrea Maria Faymonville; Shah N Jon; Karl Josef Langen; Hannah Lockau; Roland Goldbrunner; Christian Grefkes
Journal:  Neuroimage Clin       Date:  2016-11-23       Impact factor: 4.881

10.  High-grade Gliomas Exhibit Higher Peritumoral Fractional Anisotropy and Lower Mean Diffusivity than Intracranial Metastases.

Authors:  Kevin S Holly; Benjamin J Barker; Derrick Murcia; Rebekah Bennett; Piyush Kalakoti; Christina Ledbetter; Eduardo Gonzalez-Toledo; Anil Nanda; Hai Sun
Journal:  Front Surg       Date:  2017-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.